Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial

Figures & data

Figure 1 Changes in the estimated glomerular filtration rate (eGFR) and urinary albumin–creatinine ratio (UACR) in the anagliptin (ANA) and sitagliptin (SITA) groups. The bars indicate the standard errors.

Table 1 Patient Characteristics

	All Patients (n = 353)	ANA (n = 177)	SITA (n = 176)
Age	68 (10)	68 (10)	68 (9)
Men	214 (61)	110 (62)	104 (59)
Body mass index	26.0 (3.8)	26.5 (4.0)	25.9 (3.5)
Current smoker	54 (15)	30 (17)	24 (14)
Previous smoker	141 (40)	62 (35)	79 (45)
Hypertension	270 (76)	137 (77)	133 (76)
Systolic BP (mmHg)	133 (16)	134 (16)	132 (16)
Diastolic BP (mmHg)	72 (12)	74 (12)	71 (11)
Presence of CAD	159 (45)	80 (45)	79 (45)
Presence of PAD	46 (13)	24 (14)	22 (13)
Use of aspirin	153 (43)	84 (47)	69 (39)
Use of a RAAS inhibitor	206 (58)	107 (60)	99 (56)
ACEI	33 (9)	22 (12)	11 (6)
ARB	177 (50)	87 (49)	90 (51)
MRA	14 (4)	8 (5)	6 (3)
Use of a CCB	164 (46)	85 (48)	79 (45)
Use of a diuretic	52 (15)	30 (17)	22 (13)
Use of a β-receptor blocker	84 (24)	44 (21)	40 (23)
Use of a previous DPP-4 inhibitor	290 (82)	145 (82)	145 (82)
Use of a SGLT2 inhibitor	56 (16)	28 (16)	28 (16)
Fasting blood sugar (mg/dL)	142 (40)	142 (42)	139 (38)
HbA1c (%)	7.0 (0.8)	7.1 (0.8)	6.9 (0.8)
BUN (mg/dL)	16.9 (5.8)	16.7 (6.0)	17.2 (5.7)
CRE (mg/dL)	0.85 (0.28)	0.84 (0.27)	0.86 (0.29)
eGFR (mL/min/1.73 m^2)	67.92 (19.53)	69.25 (20.21)	66.59 (18.80)
UACR (mg/gCr)	221.0 (756.8)	192.0 (677.5)	250.2 (829.9)

Note: The values present the mean (SD) or number (%).

Abbreviations: ACEI, angiotensin-converting enzyme inhibitor; ANA, anagliptin; ARB, angiotensin II receptor blocker; BP, blood pressure; BUN, blood urea nitrogen; CAD, coronary artery disease; CCB, calcium channel blocker; CRE, creatinine; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; MRA, mineral corticoid receptor antagonist; PAD, peripheral artery disease; RAAS, renin-angiotensin-aldosterone system; SGLT2, sodium-glucose co-transporter 2; SITA, sitagliptin; UACR, urinary albumin–creatinine ratio.

Table 2 Clinical Parameters at Baseline and Final Follow-Up and Difference

	ANA				SITA				P value
	Baseline	Final Follow-Up	Δ	P value	Baseline	Final Follow-Up	Δ	P value	(Δ in ANA
			(Final follow-up	(Baseline vs.			(Final follow-up	(Baseline vs.	vs SITA)
			- baseline)	Final follow-up)			- baseline)	Final follow-up)
Systolic BP (mmHg)	134.0 (16.0)	132.2 (14.4)	−1.6 (14.7)	0.16	132.0 (16.0)	133.2 (15.3)	1.4 (14.8)	0.24	0.07
No.	177		170		176		170
Diastolic BP (mmHg)	73.6 (12.0)	71.7 (12.2)	−1.8 (9.8)	0.02	71.0 (11.0)	71.3 (11.9)	0.1 (10.7)	0.88	0.09
No.	177		170		176		170
CRE (mg/dL)	0.84 (0.27)	0.86 (0.29)	0.02 (0.14)	0.02	0.86 (0.29)	0.88 (0.34)	0.02 (0.16)	0.06	0.90
No.	176		169		176		170
eGFR (mL/min/1.73 m^2)	69.25 (20.21)	67.36 (20.88)	−1.66 (9.83)	0.03	66.59 (18.80)	65.66 (18.78)	−1.39 (8.02)	0.02	0.79
No.	176		169		176		170
UACR (mg/gCr)	192.0 (677.5)	169.4 (506.2)	7.7 (185.7)	0.61	250.0 (829.9)	290.3 (983.8)	57.2 (345.3)	0.04	0.12
No.	176		151		176		159

Note: The values present the mean (SD).

Abbreviations: ANA, anagliptin; BP, blood pressure; CRE, creatinine; eGFR, estimated glomerular filtration rate; SITA, sitagliptin; UACR, urinary albumin–creatinine ratio; Δ, difference.

Table 3 Relationship Between the Differences in Renal Function and Clinical Parameters

Factor	Group	ΔeGFR			ΔUACR
		r	CI	P-value	r	CI	P-value
ΔHbA1c	All	0.16	0.06–0.26	<0.01	0.01	−0.10–0.12	0.88
	ANA	0.19	0.04–0.33	0.01	−0.01	−0.17–0.15	0.89
	SITA	0.12	−0.03–0.27	0.12	0.01	−0.15–0.17	0.89
ΔLDL-C	All	0.03	−0.08–0.13	0.63	0.22	0.11–0.32	<0.01
	ANA	0.07	−0.09–0.21	0.40	−0.02	−0.18–0.14	0.77
	SITA	−0.03	−0.18–0.13	0.74	0.33	0.18–0.46	<0.01
ΔSystolic BP	All	0.20	0.10–0.30	<0.01	0.13	0.02–0.24	0.02
	ANA	0.27	0.12–0.40	<0.01	0.19	0.03–0.34	0.02
	SITA	0.13	−0.02–0.27	0.09	0.10	−0.06–0.20	0.20
ΔDiastolic BP	All	0.21	0.11–0.31	<0.01	0.12	0.01–0.23	0.03
	ANA	0.21	0.07–0.35	0.01	0.09	−0.07–0.25	0.26
	SITA	0.21	0.06–0.35	0.01	0.13	−0.03–0.28	0.11

Abbreviations: ANA, anagliptin; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, hemoglobin A1c; LDL-C, low-density lipoprotein cholesterol; SITA, sitagliptin; UACR, urinary albumin–creatinine ratio; Δ, difference.

Figure 2 Subgroup analyses of the difference in the estimated glomerular filtration rate (eGFR).

Abbreviations: ANA, anagliptin; CI, confidence interval; DPP-4, dipeptidyl peptidase-4; eGFR, estimated glomerular filtration rate; RAAS, renin–angiotensin–aldosterone system; SGLT2, sodium-glucose co-transporter 2; SITA, sitagliptin.

Figure 3 Subgroup analyses of the difference in the urinary albumin–creatinine ratio (UACR).

Abbreviations: ANA, anagliptin; CI, confidence interval; DPP-4, dipeptidyl peptidase-4; eGFR; RAAS, renin–angiotensin–aldosterone system; SGLT2, sodium-glucose co-transporter 2; SITA, sitagliptin; UACR, urinary albumin–creatinine ratio.